The PNBIL reduces AD symptoms in mouse models by recognizing and inhibiting Aβ aggregation, as well as facilitating microglia-mediated clearance, after being modified with Aβ and interleukin-1β (IL-1β) fragments [98]. The gene discussed is IL1B; the disease is Alzheimer disease.